Jasper Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Jasper Therapeutics, Inc. (JSPR) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-71.27-64.47-37.69-30.64-31.67
Depreciation & Amortization1.371.110.980.380.00
Stock Based Compensation6.625.214.091.051.21
Change in Working Capital0.175.10-0.651.621.30
Change in Accounts Receivable0.000.66-0.660.600.00
Change in Accounts Payable-0.122.38-2.152.940.36
Change in Other Working Capital0.302.06-5.39-9.090.94
Other Operating Activities0.500.98-5.39-9.0910.90
Net Cash from Operating Activities-62.60-52.07-45.86-33.68-18.27
Investing Activities
Capital Expenditures-0.55-0.27-0.58-2.430.00
Other Investing Activities0.020.000.000.000.00
Net Cash from Investing Activities-0.53-0.27-0.58-2.430.00
Financing Activities
Debt Repayment0.00-0.02-5.73-9.280.00
Common Stock Issued47.20101.930.03-5.290.05
Common Stock Repurchased0.00-0.960.000.000.00
Other Financing Activities0.69-0.960.0089.980.00
Net Cash from Financing Activities47.88100.970.06100.9711.29
Summary
Net Change in Cash-15.2548.64-46.3864.86-6.98
Cash at Beginning of Period87.3038.6785.0520.180.00
Cash at End of Period72.0587.3038.6785.050.00
Free Cash Flow-63.15-52.33-46.43-36.11-18.27